Eplerenone

1. Barkley RA: Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997; 121: 6594 Graybiel AM: The basal ganglia. Curr Biol 2000; 10: R509R511 3. Swanson J, Volkow N: Pharmacokinetic and pharmacodynamic properties of methylphenidate in humans, in Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Edited by Solanto MV, Arnsten AFT, Castellanos FX. Oxford, UK, Oxford University Press, 2001, pp 259282 4. Castellanos FX, Giedd JN, Marsh WL, Hamburger SD, Vaituzis AC, Dickstein DP, Sarfatti SE, Vauss YC, Snell JW, Lange N, Kaysen D, Krain AL, Ritchie GF, Rajapakse JC, Rapoport JL: Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 607616 Castellanos FX, Giedd JN, Berquin PC, Walter JM, Sharp W, Tran T, Vaituzis AC, Bastain T, Blumenthal J, Nelson J, Zijdenbos A, Evans AC, Rapoport JL: Quantitative brain magnetic resonance imaging in girls with attention-deficit hyperactivity disorder. Arch Gen Psychiatry 2001; 58: 289295 Mostofsky SH, Reiss AL, Lockhart P, Denckla MB: Evaluation of cerebellar size in attention-deficit hyperactivity disorder. J Child Neurol 1998; 13: 434439 Berquin PC, Giedd JN, Jacobsen LK, Hamburger SD, Krain AL, Rapoport JL, Castellanos FX: Cerebellum in attention-deficit hyperactivity disorder--a morphometric MRI study. Neurology 1998; 50: 10871093 Ikai Y, Takada M, Mizuno N: Single neurons in the ventral tegmental area that project to both the cerebral and cerebellar cortical areas by way of axon collaterals. Neuroscience 1994; 61: 925934 Ikai Y, Takada M, Shinonaga Y, Mizuno N: Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of. The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled `New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 1517, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and antiCD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma. Bakhai et al. 2 ; studied the impact of diabetes on clinical and economic outcomes of PCI in the elderly, using an administrative database. There was a trend toward higher mortality 12.1% vs. 8.6%, p 0.081 ; , more clinical restenosis 11.9% vs. 8.4%, p 0.001 ; , and more repeat procedures in the diabetic patients PCI 9.2% vs. 7.0%, p 0.004, CABG 3.3% vs. 2.0%, p 0.012 ; . Costs at one year were also higher in the diabetic patients, whether there was restenosis , 158 vs. , 178, p 0.001 ; or no restenosis , 937 vs. , 299, p 0.001 ; . Also, the cost of restenosis was higher in diabetic patients. Cardiovascular care for diabetics remains a serious problem; this study documents not only poor outcome in older diabetics, but higher costs as well.

Side effects are usually fewer if the dose is less than 1 g per day: gastro-intestinal disturbances dry mouth bradycardia slow pulse rate ; worsening of angina orthostatic hypotension postural hypotension ; sedation, headaches, dizziness myalgia muscle pain ; , arthralgia joint pain ; or paraesthesia numbness ; nightmares, mild psychosis , depression parkinsonism bell's palsy abnormal liver functions tests and hepatitis pancreatitis haemolytic anaemia bone marrow suppresion leading to thrombocytopenia low platelets ; or leucopenia low white blood cells ; hypersensitivity reactions including lupus erythematosus -like syndrome, myocarditis heart muscle inflammation ; , pericarditis and rashes ejaculatory failure, impotence, decreased libido, gynecomastia breast enlargement in men ; , hyperprolactinaemia and amenorrhoea note that if used in pregnant women, it may cause a positive coombs test footnotes british national formulary 45 march 2003 antihypertensives c02 ; and diuretics c03 ; antiadrenergic agents including alpha ; centrally acting clonidine , guanfacine , methyldopa , moxonidine , rescinnamine , reserpine , rilmenidine ; ganglion-blocking nicotinic antagonist mecamylamine , trimethaphan ; peripherally acting prazosin , guanethidine , indoramin , doxazosin ; vasodilators diazoxide hydralazine minoxidil nitroprusside phentolamine other antihypertensives serotonin antagonist ketanserin ; endothelin receptor antagonist bosentan , ambrisentan , sitaxsentan ; low ceiling diuretics thiazide bendroflumethiazide , chlorothiazide , hydrochlorothiazide ; chlortalidone indapamide quinethazone mersalyl metolazone theobromine cicletanine high ceiling diuretics loop diuretic bumetanide , furosemide , torasemide ; potassium-sparing diuretics esc blockers amiloride , triamterene ; aldosterone antagonists spironolactone , eplerenone , potassium canrenoate , canrenone ; this entry is from wikipedia, the leading user-contributed encyclopedia and eprosartan.
Pulmonale. These studies suggest that corticosteroids are generally detrimental in uncomplicated congestive heart failure. Greater deterioration appeared in subjects having the more severe degrees of decompensation, suggesting.
Identified in patients with early-onset hypertension that is exacerbated by pregnancy 26 ; . The underlying mechanism of the pregnancy effect is that progesterone, which antagonizes MR function, activates the mutant receptor. It has been reported that other antimineralocorticoid steroids, such as spironolactone, also activate the MR S810L mutant 26 ; . We show here that these steroidal MR antagonists are partial agonists antagonists of the MR S810L mutant, similar to the effect of cortisol on wildtype MR LBD. Moreover, these ligands are as good as aldosterone and cortisol ; in recruiting LXXLL coactivator peptides to the S810L mutant receptor Fig. 7 ; , also similar to the effect of cortisol on cofactor interactions with wildtype MR LBD. The interesting switch of cortisol from antagonist salt bridge mutations ; to partial agonist wildtype ; and then to full agonist S810L mutation ; , and the interaction of MR LBD with cofactor peptides in the presence of various ligands led us to propose that there are multiple mechanisms to activate MR Fig. 8 ; . These mechanisms include interaction with 1 ; the LXXLL containing coactivators, 2 ; other unidentified cofactors that differentiate the effects of aldosterone and cortisol, and 3 ; both. In the unliganded state or in the antagonist such as eplerenone ; bound state, MR adopts a tran.deleted.ionally neutral conformation. We should point out that there are certainly conformational differences between the unliganded receptor and the antagonist bound receptor since unliganded MR resides in the cytoplasm and antagonist bound MR is translocated into nucleus 50 ; and data not shown ; . However, from the tran.deleted.ional activity point of view, their LBDs are in a basal neutral conformation without activation or repression functions and erbitux. TSurface Ig expression not detectable; monoclonality could be shown in the immunoglobulin patient no. 9, IgMA; patient no. 12, IgMK ; . Patient nos. 4 and 16 were monoclonal for IgG heavy chain all other cases monoclonal.
Whereas the plasma corticosterone level did not differ between DS-CHF and control rats. We also found that myocardial expression of the 11 -HSD1 gene was greatly increased in DS-CHF rats, whereas that of the 11 -HSD2 gene was virtually undetectable in the heart of either DS-CHF or control rats, consistent with previous observations in the neonatal rat heart.29 The intracellular concentration of corticosterone available for binding to the MR is, thus, likely much higher than that of aldosterone in the heart of DS-CHF rats, suggesting that most MRs in the heart of these animals are occupied by corticosterone. Loss-of-function mutations or inhibition of 11 -HSD2 also result both in activation of the MR by glucocorticoids and in salt-sensitive low-renin, lowaldosterone ; hypertension.30 We speculate that, in DS-CHF rats, the increased expression of 11 -HSD1 in the virtual absence of 11 -HSD2 may contribute to local glucocorticoid excess in the heart. Our observation that the increase in 11 -HSD1 gene expression in the heart of DS-CHF rats was inhibited by eplerenone suggests that glucocorticoidmediated MR activation might be responsible for upregulation of the expression of this gene, 31 forming a positive feedback loop, and that blockade of the MR with eplerenone interrupts this loop. Two cytochrome P450 enzymes are responsible for catalyzing the terminal steps in corticosterone and aldosterone synthesis: 11 -hydroxylase P45011 or CYP11B1 ; and aldosterone synthase P450aldo or CYP11B2 ; , respectively. Expression of the CYP11B1 gene was minimal and that of the CYP11B2 gene was and ergotamine. AVID Maraniss, author of the best book on Bill Clinton First in His Class ; , has said that the famous line "winning isn't everything, it's the only thing" lifted from a 1953 John Wayne movie ; explains Clinton better than it does Vince Lombardi. Lombardi had a more complex moral outlook, shaped by family, church, and. 32. Jones SC, Saunders HJ, Pollock CA 1999 High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabet Med 16: 932938 33. Naray-Fejes-Toth A, Fejes-Toth G 2000 The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int 57: 1290 1294 Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H 1994 Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316 24320 Wehling M 1995 Nongenomic aldosterone effects: the cell membrane as a specific target of mineralocorticoid action. Steroids 60: 153156 36. Ebata S, Muto S, Okada K, Nemoto J, Amemiya M, Saito T, Asano Y 1999 Aldosterone activates Na H exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int 56: 1400 1412 Manegold JC, Falkenstein E, Wehling M, Christ M 1999 Rapid aldosterone effects on tyrosine phosphorylation in vascular smooth muscle cells. Cell Mol Biol Noisy-le-grand ; 45: 805 813 Alzamora R, Michea L, Marusic ET 2000 Role of 11 -hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35: 1099 1104 Yamamoto N, Yasue H, Mizuno Y, Yoshimura M, Fujii H, Nakayama M, Harada E, Nakamura S, Ito T, Ogawa H 2002 Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 39: 958 962 Mihailidou AS, Mardini M, Funder JW, Raison M 2002 Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. Hypertension 40: 124 129 Barbato JC, Mulrow PJ, Shapiro JI, Franco-Saenz R 2002 Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension 40: 130 135 Kayes-Wandover KM, White PC 2000 Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85: 2519 2525 Young MJ, Clyne CD, Cole TJ, Funder JW 2001 Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 86: 51215126 44. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, Harada E, Nakayama M, Nakamura S, Ito T, Shimasaki Y, Saito Y, Nakao K 2001 Aldosterone production is activated in failing ventricle in humans. Circulation 103: 7277 45. Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y, Sakamoto T, Yamamuro M, Saito Y, Nakao K, Yasue H, Ogawa H 2002 Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87: 3936 3940 Sato A, Funder JW 1996 High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 137: 4145 4153 Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH 2002 Aldosterone and d-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39: 756 760 Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 38713878 49. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709 717 Epstein M, Buckalew Jr V, Martinez F, Altamirano J, Roniker B, Kleiman J, Krause S, the Eplerenone 021 Investigators 2002 Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone enalapril combination therapy in diabetic hypertensives with microalbuminuria. J Hypertens 15: OR-54 51. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW 1999 C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19: 972978 52. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM 2000 Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study IRAS ; . Circulation 102: 42 47 Pradhan AD, Ridker 2002 Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23: 831 834 Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE 2000 Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85: 336 344 Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB 2000 Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219 1227 Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ 2002 Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 87: 448 452 Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE 1998 Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32: 965971 and erlotinib.
24 82. Ospina JA, Brevig HN, Krause DN, and Duckles SP. Estrogen suppresses IL-1betamediated induction of COX-2 pathway in rat cerebral blood vessels. J Physiol Heart Circ Physiol 286: H2010-2019, 2004. 83. Ospina JA, Duckles SP, and Krause DN. 17beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. J Physiol Heart Circ Physiol 285: H241-250, 2003. 84. Ospina JA, Krause DN, and Duckles SP. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33: 600605, 2002. Palmon SC, Williams MJ, Littleton-Kearney MT, Traystman RJ, Kosk-Kosicka D, and Hurn PD. Estrogen increases cGMP in selected brain regions and in cerebral microvessels. J Cereb Blood Flow Metab 18: 1248-1252, 1998. Park EM, Cho S, Frys KA, Glickstein SB, Zhou P, Anrather J, Ross ME, and Iadecola C. Inducible nitric oxide synthase contributes to gender differences in ischemic brain injury. J Cereb Blood Flow Metab 26: 392-401, 2006. Pawlak J, Karolczak M, Krust A, Chambon P, and Beyer C. Estrogen receptor-alpha is associated with the plasma membrane of astrocytes and coupled to the MAP Src-kinase pathway. Glia 50: 270-275, 2005. Pedersen NG, Pedersen SH, Dalsgaard T, Lund CO, Nilas L, and Ottesen B. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits. Maturitas 49: 304-314, 2004. Pelligrino DA, and Galea E. Estrogen and cerebrovascular physiology and pathophysiology. Jpn J Pharmacol 86: 137-158, 2001. Pelligrino DA, Santizo R, Baughman VL, and Wang Q. Cerebral vasodilating capacity during forebrain ischemia: effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. Neuroreport 9: 3285-3291, 1998. Pelligrino DA, Ye S, Tan F, Santizo RA, Feinstein DL, and Wang Q. Nitric-oxidedependent pial arteriolar dilation in the female rat: effects of chronic estrogen depletion and repletion. Biochem Biophys Res Commun 269: 165-171, 2000. Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E, and Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. J Obstet Gynecol 169: 1226-1232, 1993. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, and Vignali M. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 76: 235-240, 2001. Perez GJ. Dual effect of tamoxifen on arterial KCa channels does not depend on the presence of the beta1 subunit. J Biol Chem 280: 21739-21747, 2005. Phiel KL, Henderson RA, Adelman SJ, and Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett 97: 107113, 2005. Purohit A, and Reed MJ. Regulation of estrogen synthesis in postmenopausal women. Steroids 67: 979-983, 2002. Qin X, Hurn PD, and Littleton-Kearney MT. Estrogen restores postischemic sensitivity to the thromboxane mimetic U46619 in rat pial artery. J Cereb Blood Flow Metab 25: 1041-1046, 2005. The nutrient medium containing sucrose, yeast extract and K2HPO4 ; , temperature and initial pH conditions were optimised for batch dextran production in shake flask fermentations using a strain of Leuconostoc mesenteroides NRRL B 512 F ; . A 25-1 fractional factorial central composite experimental design was attempted. Multistage Monte Carlo optimization program was used to maximize the multiple regression equation obtained. The optimal values of tested variables for maximal dextran production were found to be: sucrose, 300 g l; yeast extract, 10 g l; K2HPO4, 30 g l; temperature, 23 C and initial pH 8.3 with a predicted dextran yield of 154 g l. The new heteropolysaccharide S-130, prepared by fermentation of an unnamed Alcaligenes species, ATCC 31555 has valuable properties as a thickening, suspending and stabilizing agent in aqueous systems. It is especially useful in formulating oil well drilling fluids and muds. Its chemical composition is 2.8-7.5% acyl groups, 11.6-14.9% glucuronic acid; and the neutral sugars mannose, glucose and rhamnose, in the approximate molar ratio 1: 2 and ertapenem.

Salzman C 2000 ; , Psychiatric Medications for Older Adults: The Concise Guide. New York: The Guilford Press and esmolol. Ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 18311838 White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA 2003 Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 10211026 Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL 2004 Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. J Cardiol 93: 990996 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 13091321 Gomez-Sanchez EP, Venkataraman MT, Thwaites D, Fort C 1990 ICV infusion of corticosterone antagonizes ICValdosterone hypertension. J Physiol 258: E649E653 Young MJ, Funder JW 1996 The renin-angiotensin-aldosterone system in experimental mineralocorticoid-saltinduced cardiac fibrosis. J Physiol 271: E883E888 Funder JW 2000 Aldosterone and mineralocorticoid receptors: orphan questions. Kidney Int 57: 13581363 Hermanson O, Glass CK, Rosenfeld MG 2002 Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 13: 5560 Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in tran.deleted.ional co-activators mediates binding to nuclear receptors. Nature 387: 733736 Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12: 33433356 Ding XF, Anderson CM, Ma H, Hong H, Uht RM, Kushner PJ, Stallcup MR 1998 Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 GRIP1 ; and steroid receptor coactivator 1 SRC-1 ; : multiple motifs with different binding specificities. Mol Endocrinol 12: 302313 Hu X, Lazar MA 1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402: 9396 Kalkhoven E, Valentine JE, Heery DM, Parker MG 1998 Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate tran.deleted.ion by the oestrogen receptor. EMBO J 17: 232243 Lee SK, Jung SY, Kim YS, Na SY, Lee YC, Lee JW 2001 Two distinct nuclear receptor-interaction domains and CREB-binding protein-dependent transactivation function of activating signal cointegrator-2. Mol Endocrinol 15: 241254 Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829839 Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM 2002 Peroxisome proliferator-activated receptor coactivator 1 PGC-1 ; , a novel PGC-1-related tran.deleted.ion coactivator associated with host cell factor. J Biol Chem 277: 16451648 Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW 1998 The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 AF1 ; and AF2 domains of steroid receptors. J Biol Chem 273: 1210112108 Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME 2000 Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int 57: 12501255.
7. The Acute Infarction Ramipril Efficacy AIRE ; Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with evidence of heart failure. Lancet 1993; 342: 821828. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN Randomised Trial. Lancet 2001; 357: 13851390. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 13091321. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of and estramustine and eplerenone. Medical and Dental University Graduate School in Japan, investigated whether vascular angiotensin-converting enzyme ACE ; gene expression is up-regulated in aldosterone-induced hypertensive rats Aldorats ; , whether local RAS and oxidative stress are involved in the development of hypertension and vascular injury, and what molecular mechanisms underlie the aldosteroneinduced vascular injury and oxidative stress. The study showed for the first time that ACE mRNA expression and enzyme activity were increased in the aortic tissue of Aldo-rats, and aldosterone's effects were completely blocked by a selective MR antagonist eplerenone ; . Aldosterone-induced cardiovascular injury, increased vascular pro. 5 because aldosterone increases collagen, leading to aortic fibrosis, 7 we examined, in angioplastied porcine coronary arteries, whether chronic administration of the mineralocorticoid antagonist eplerenone affects collagen accumulation, constrictive remodeling, and the size of the developing neointima and eszopiclone. Glomeruli 38 ; . Studies have demonstrated the presence of Sgk1 in both mesangial cells and podocytes 39, 40 ; . Quinkler et al. 16 ; demonstrated increased expression of aldosterone effectors, including Sgk1, in kidney biopsies of patients with heavy proteinuria, implicating the close relationship between Sgk1 and proteinuria. The pivotal role of Sgk1 in the pathogenesis of proteinuria also is suggested by the report that gene targeting of Sgk1 protects against DOCA salt-induced albuminuria 41 ; . Oxidative stress is postulated to be an important mediator of aldosterone actions 14 ; . Our data indicated that oxidative stress markers are elevated in SHR cp and that tempol ameliorated proteinuria and podocyte injury, along with inhibition of the enhanced Sgk1 expression. Importantly, eplerenone suppressed the elevated oxidative stress markers in SHR cp. Sgk1 regulation by oxidative stress was demonstrated previously in other cells 42 ; . These results suggest that aldosterone increases ROS generation, which causes Sgk1 upregulation and podocyte injury. Nishiyama et al. 14, 43 ; demonstrated that aldosterone increases ROS, which in turn activate extracellular signalregulated kinase 1 2, c-Jun N-terminal kinase, and big mitogenactivated protein kinase BMK1 ; but not p38 mitogen-activated protein kinase in rat renal cortex and cultured mesangial cells!